EGOM, Emmanuel Eroume-A., Rebabonye B. PHARITHI, Soressa HESSE, Neasa STARR, Richard ARMSTRONG, Habitha Mohammed SULAIMAN, Katarina GAZDIKOVA, Ioana MOZOS, Martin CAPRNDA, Peter KUBATKA, Peter KRUŽLIAK, Barkat KHAN, Ludovit GASPAR and Vincent M. G. MAHER. Latest Updates on Lipid Management. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION. NORTHCOTE: ADIS INT LTD, 2019, vol. 26, No 2, p. 85-100. ISSN 1120-9879. Available from: https://dx.doi.org/10.1007/s40292-019-00306-8.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Latest Updates on Lipid Management
Authors EGOM, Emmanuel Eroume-A. (372 Ireland), Rebabonye B. PHARITHI (372 Ireland), Soressa HESSE (372 Ireland), Neasa STARR (372 Ireland), Richard ARMSTRONG (372 Ireland), Habitha Mohammed SULAIMAN (372 Ireland), Katarina GAZDIKOVA (703 Slovakia), Ioana MOZOS (642 Romania), Martin CAPRNDA (703 Slovakia), Peter KUBATKA (703 Slovakia), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution), Barkat KHAN (372 Ireland), Ludovit GASPAR (703 Slovakia) and Vincent M. G. MAHER (372 Ireland).
Edition HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, NORTHCOTE, ADIS INT LTD, 2019, 1120-9879.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30212 Surgery
Country of publisher New Zealand
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/19:00110192
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s40292-019-00306-8
UT WoS 000463743900001
Keywords in English ASCVD; Atherosclerotic cardiovascular disease; Cholesterol; Lipid management; Triglycerides
Tags 14110121, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 16/7/2019 16:00.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. Despite the clinical long-term and near-term benefits of lowering cholesterol in, respectively, primary and secondary prevention of ASCVD, cholesterol levels remain under-treated, with many patients not achieving their recommended targets. The present article will review the latest updates on lipid management with emphases on the different classes of cholesterol-lowering agents and their clinical uses.
PrintDisplayed: 4/10/2024 04:54